NewcelX Ltd. - Ordinary Shares (NCEL) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$3.82
Trend Context
Mixed / range
Latest briefing
What's happening with NCEL
globenewswire.com8 Jul 2026
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
The appointment follows New c elX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101 , providing a clear regulatory pathway toward clinical trials
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com1 Jul 2026
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com15 Jun 2026
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
27 May 2026
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
